{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:25:16Z","timestamp":1787793916032,"version":"build-2784847793"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02382-3","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:53:12Z","timestamp":1778172792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current landscape of migraine care with expert consensus from East Asia"],"prefix":"10.1186","volume":"27","author":[{"given":"Shuu-Jiun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyung","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Kun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"1","key":"2382_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-024-01798-z","volume":"25","author":"J Cen","year":"2024","unstructured":"Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F (2024) Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the Global Burden of Disease Study 2021. J Headache Pain 25(1):96. https:\/\/doi.org\/10.1186\/s10194-024-01798-z","journal-title":"J Headache Pain"},{"issue":"1","key":"2382_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD 2019. J Headache Pain 21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"issue":"10053","key":"2382_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/s0140-6736(16)31678-6","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545\u20131602. https:\/\/doi.org\/10.1016\/s0140-6736(16)31678-6","journal-title":"Lancet"},{"issue":"1","key":"2382_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region. Pain Ther 14(1):297\u2013315. https:\/\/doi.org\/10.1007\/s40122-024-00690-7","journal-title":"Pain Ther"},{"key":"2382_CR5","doi-asserted-by":"publisher","first-page":"1402569","DOI":"10.3389\/fneur.2024.1402569","volume":"15","author":"A Ozge","year":"2024","unstructured":"Ozge A, Baykan B, Bicakci S, Ertas M, Atalar AC, Gumru S et al (2024) Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications. Front Neurol 15:1402569. https:\/\/doi.org\/10.3389\/fneur.2024.1402569","journal-title":"Front Neurol"},{"issue":"2","key":"2382_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40122-024-00576-8","volume":"13","author":"A Albilali","year":"2024","unstructured":"Albilali A, Al-Hashel J, Elchami Z, Al Rukn S, Al Madani AB, AlTunaiji M et al (2024) Unmet needs of patients living with migraine in the Gulf Cooperation Council (GCC) countries. Pain Ther 13(2):201\u2013210. https:\/\/doi.org\/10.1007\/s40122-024-00576-8","journal-title":"Pain Ther"},{"issue":"5","key":"2382_CR7","doi-asserted-by":"publisher","first-page":"38534","DOI":"10.52965\/001c.38534","volume":"10","author":"AA Berger","year":"2022","unstructured":"Berger AA, Winnick A, Carroll AH, Welschmeyer A, Li N, Colon M et al (2022) Rimegepant for the treatment of migraine. Health Psychol Res 10(5):38534. https:\/\/doi.org\/10.52965\/001c.38534","journal-title":"Health Psychol Res"},{"issue":"8","key":"2382_CR8","doi-asserted-by":"publisher","first-page":"333102424125266","DOI":"10.1177\/03331024241252666","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 44(8):3331024241252666. https:\/\/doi.org\/10.1177\/03331024241252666","journal-title":"Cephalalgia"},{"issue":"9","key":"2382_CR9","doi-asserted-by":"publisher","first-page":"333102424126973","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F, Sacco S, Diener HC, Ashina M, Al-Khazali HM, Ashina S et al (2024) International Headache Society global practice recommendations for preventive pharmacological treatment of migraine. Cephalalgia 44(9):3331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735","journal-title":"Cephalalgia"},{"issue":"10283","key":"2382_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/S0140-6736(20)32160-7","journal-title":"Lancet"},{"issue":"1","key":"2382_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, Komori M, Stretton S, Rajan N et al (2019) Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain 20(1):111. https:\/\/doi.org\/10.1186\/s10194-019-1062-4","journal-title":"J Headache Pain"},{"issue":"13","key":"2382_CR12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1177\/0333102413484990","volume":"33","author":"BK Kim","year":"2013","unstructured":"Kim BK, Chung YK, Kim JM, Lee KS, Chu MK (2013) Prevalence, clinical characteristics and disability of migraine and probable migraine: a nationwide population-based survey in Korea. Cephalalgia 33(13):1106\u20131116. https:\/\/doi.org\/10.1177\/0333102413484990","journal-title":"Cephalalgia"},{"issue":"1","key":"2382_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N (2024) Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain 25(1):19. https:\/\/doi.org\/10.1186\/s10194-024-01722-5","journal-title":"J Headache Pain"},{"issue":"5","key":"2382_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3988\/jcn.2023.0485","volume":"20","author":"KY Kim","year":"2024","unstructured":"Kim KY, Ko HY, Bea S, Lee HJ, Shin JY, Chu MK (2024) Treatment patterns and persistence among patients newly diagnosed with migraine in South Korea: a retrospective analysis of health claims data. J Clin Neurol 20(5):529\u2013536. https:\/\/doi.org\/10.3988\/jcn.2023.0485","journal-title":"J Clin Neurol"},{"issue":"Supplement1","key":"2382_CR15","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1212\/WNL.0000000000212193","volume":"104","author":"K Parikh","year":"2025","unstructured":"Parikh K, Lipton R, Howarth A, Wilson L, Bodhani A, Duan M et al (2025) Impact of triptan insufficient response on medication use, health care utilization, and costs: a retrospective claims study (P1-12.002). Neurology 104(Supplement1):5190. https:\/\/doi.org\/10.1212\/WNL.0000000000212193","journal-title":"Neurology"},{"issue":"7","key":"2382_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1080\/13696998.2019.1590841","volume":"22","author":"A Donnet","year":"2019","unstructured":"Donnet A, Emery C, Aly S, Allaf B, Cayre F, Mahieu N et al (2019) Migraine burden and costs in France: a nationwide claims database analysis of triptan users. J Med Econ 22(7):616\u2013624. https:\/\/doi.org\/10.1080\/13696998.2019.1590841","journal-title":"J Med Econ"},{"issue":"1","key":"2382_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40120-021-00304-w","volume":"11","author":"A Gendolla","year":"2022","unstructured":"Gendolla A, Rauer N, Kraemer S, Schwerdtner I, Straube A (2022) Epidemiology, demographics, triptan contraindications, and prescription patterns of patients with migraine: a German claims database study. Neurol Ther 11(1):167\u2013183. https:\/\/doi.org\/10.1007\/s40120-021-00304-w","journal-title":"Neurol Ther"},{"key":"2382_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/jpr.S371887","volume":"16","author":"H Zhao","year":"2023","unstructured":"Zhao H, Xiao Z, Zhang L, Ford J, Zhong S, Ye W et al (2023) Real-world treatment patterns and outcomes among patients with episodic migraine in China: results from the Adelphi Migraine Disease Specific Programme\u2122. J Pain Res 16:357\u2013371. https:\/\/doi.org\/10.2147\/jpr.S371887","journal-title":"J Pain Res"},{"issue":"1","key":"2382_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s10194-024-01832-0","volume":"25","author":"ZF Chen","year":"2024","unstructured":"Chen ZF, Kong XM, Yang CH, Li XY, Guo H, Wang ZW (2024) Global, regional, and national burden and trends of migraine among youths and young adults aged 15\u201339 years from 1990 to 2021: findings from the global burden of disease study 2021. J Headache Pain 25(1):131. https:\/\/doi.org\/10.1186\/s10194-024-01832-0","journal-title":"J Headache Pain"},{"key":"2382_CR20","doi-asserted-by":"publisher","first-page":"1169795","DOI":"10.3389\/fneur.2023.1169795","volume":"14","author":"C Iba","year":"2023","unstructured":"Iba C, Ohtani S, Lee MJ, Huh S, Watanabe N, Nakahara J et al (2023) Migraine triggers in Asian countries: a narrative review. Front Neurol 14:1169795. https:\/\/doi.org\/10.3389\/fneur.2023.1169795","journal-title":"Front Neurol"},{"issue":"3","key":"2382_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3988\/jcn.2014.10.3.236","volume":"10","author":"JW Park","year":"2014","unstructured":"Park JW, Moon HS, Kim JM, Lee KS, Chu MK (2014) Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol 10(3):236\u2013243. https:\/\/doi.org\/10.3988\/jcn.2014.10.3.236","journal-title":"J Clin Neurol"},{"issue":"10","key":"2382_CR22","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1046\/j.1468-2982.2001.00294.x","volume":"21","author":"SR Lu","year":"2001","unstructured":"Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ (2001) Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia 21(10):980\u2013986. https:\/\/doi.org\/10.1046\/j.1468-2982.2001.00294.x","journal-title":"Cephalalgia"},{"issue":"4","key":"2382_CR23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10194-010-0217-0","volume":"11","author":"LJ Stovner","year":"2010","unstructured":"Stovner LJ, Andree C (2010) Prevalence of headache in Europe: a review for the Eurolight Project. J Headache Pain 11(4):289\u2013299. https:\/\/doi.org\/10.1007\/s10194-010-0217-0","journal-title":"J Headache Pain"},{"issue":"5","key":"2382_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM et al (2024) Prevalence and burden of migraine in the United States: a systematic review. Headache 64(5):516\u2013532. https:\/\/doi.org\/10.1111\/head.14709","journal-title":"Headache"},{"issue":"4","key":"2382_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/j.1526-4610.2011.02061.x","volume":"52","author":"S Yu","year":"2012","unstructured":"Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J et al (2012) The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache 52(4):582\u2013591. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02061.x","journal-title":"Headache"},{"issue":"6","key":"2382_CR26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1526-4610.1996.3606379.x","volume":"36","author":"EE Alders","year":"1996","unstructured":"Alders EE, Hentzen A, Tan CT (1996) A community-based prevalence study on headache in Malaysia. Headache 36(6):379\u2013384. https:\/\/doi.org\/10.1046\/j.1526-4610.1996.3606379.x","journal-title":"Headache"},{"issue":"6","key":"2382_CR27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1468-2982.2000.00085.x","volume":"20","author":"SJ Wang","year":"2000","unstructured":"Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC (2000) Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia 20(6):566\u2013572. https:\/\/doi.org\/10.1046\/j.1468-2982.2000.00085.x","journal-title":"Cephalalgia"},{"issue":"1","key":"2382_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. https:\/\/doi.org\/10.1186\/s10194-018-0907-6","journal-title":"J Headache Pain"},{"issue":"2","key":"2382_CR29","first-page":"88","volume":"13","author":"RW Evans","year":"2014","unstructured":"Evans RW (2014) The clinical features of migraine with and without aura: updates on the clinical features of migraine, especially migraine with aura. Pract Neurol 13(2):88\u201395","journal-title":"Pract Neurol"},{"issue":"4","key":"2382_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.17340\/jkna.2015.4.6","volume":"33","author":"N Jo","year":"2015","unstructured":"Jo N, Kim B-K (2015) Clinical characteristics of migraine with aura in Korean: a clinic based study. J Korean Neurol Assoc 33(4):278\u2013281","journal-title":"J Korean Neurol Assoc"},{"issue":"1","key":"2382_CR31","doi-asserted-by":"publisher","first-page":"22611","DOI":"10.1038\/s41598-024-74253-3","volume":"14","author":"N Imai","year":"2024","unstructured":"Imai N, Matsumori Y (2024) Different effects of migraine associated features on headache impact, pain intensity, and psychiatric conditions in patients with migraine. Sci Rep 14(1):22611. https:\/\/doi.org\/10.1038\/s41598-024-74253-3","journal-title":"Sci Rep"},{"issue":"1","key":"2382_CR32","first-page":"1","volume":"15","author":"J Roh","year":"1997","unstructured":"Roh J, Kim J, Ahn Y (1997) Epidemiological and clinical characteristics of migraine in Korea. J Korean Neurol Assoc 15(1):1\u201318","journal-title":"J Korean Neurol Assoc"},{"issue":"3","key":"2382_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1046\/j.1468-2982.1991.1103129.x","volume":"11","author":"BK Rasmussen","year":"1991","unstructured":"Rasmussen BK, Jensen R, Olesen J (1991) A population-based analysis of the diagnostic criteria of The International Headache Society. Cephalalgia 11(3):129\u2013134. https:\/\/doi.org\/10.1046\/j.1468-2982.1991.1103129.x","journal-title":"Cephalalgia"},{"issue":"1","key":"2382_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1212\/wnl.47.1.52","volume":"47","author":"WF Stewart","year":"1996","unstructured":"Stewart WF, Lipton RB, Liberman J (1996) Variation in migraine prevalence by race. Neurology 47(1):52\u201359. https:\/\/doi.org\/10.1212\/wnl.47.1.52","journal-title":"Neurology"},{"issue":"6","key":"2382_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10194-008-0077-z","volume":"9","author":"MB Russell","year":"2008","unstructured":"Russell MB, Kristiansen HA, Saltyte-Benth J, Kvaerner KJ (2008) A cross-sectional population-based survey of migraine and headache in 21,177 Norwegians: The Akershus Sleep Apnea Project. J Headache Pain 9(6):339\u2013347. https:\/\/doi.org\/10.1007\/s10194-008-0077-z","journal-title":"J Headache Pain"},{"issue":"5","key":"2382_CR36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/head.14308","volume":"62","author":"YH Tu","year":"2022","unstructured":"Tu YH, Wang YF, Yuan H, Chen SP, Tzeng YS, Chen WT et al (2022) Most bothersome symptoms in patients with migraine: a hospital-based study in Taiwan. Headache 62(5):596\u2013603. https:\/\/doi.org\/10.1111\/head.14308","journal-title":"Headache"},{"issue":"11","key":"2382_CR37","doi-asserted-by":"publisher","first-page":"e0289729","DOI":"10.1371\/journal.pone.0289729","volume":"18","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Lee HJ, Lee SH, Cho S, Kim KM, Chu MK (2023) Most bothersome symptom in migraine and probable migraine: a population-based study. PLoS ONE 18(11):e0289729. https:\/\/doi.org\/10.1371\/journal.pone.0289729","journal-title":"PLoS ONE"},{"key":"2382_CR38","doi-asserted-by":"publisher","unstructured":"Munjal S, Singh P, Reed ML, Fanning K, Schwedt TJ, Dodick DW et al (2020) Most bothersome symptom in persons with migraine: results from the Migraine in America Symptoms and Treatment (MAST) study. Headache 60(2):416\u2013429. https:\/\/doi.org\/10.1111\/head.13708","DOI":"10.1111\/head.13708"},{"issue":"10","key":"2382_CR39","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1111\/head.13636","volume":"59","author":"M Ashina","year":"2019","unstructured":"Ashina M, Vasudeva R, Jin L, Lombard L, Gray E, Doty EG et al (2019) Onset of efficacy following oral treatment with lasmiditan for the acute treatment of migraine: integrated results from 2 randomized double-blind placebo-controlled phase 3 clinical studies. Headache 59(10):1788\u20131801. https:\/\/doi.org\/10.1111\/head.13636","journal-title":"Headache"},{"issue":"1","key":"2382_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J, Xia F, Cai Y, Zhang S et al (2023) Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain 24(1):79. https:\/\/doi.org\/10.1186\/s10194-023-01619-9","journal-title":"J Headache Pain"},{"issue":"1","key":"2382_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s10194-023-01634-w","volume":"24","author":"Y Yang","year":"2023","unstructured":"Yang Y, Cao Y (2023) Rising trends in the burden of migraine and tension-type headache among adolescents and young adults globally, 1990 to 2019. J Headache Pain 24(1):94. https:\/\/doi.org\/10.1186\/s10194-023-01634-w","journal-title":"J Headache Pain"},{"issue":"12","key":"2382_CR42","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","volume":"270","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Lof E et al (2023) Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol 270(12):5692\u20135710. https:\/\/doi.org\/10.1007\/s00415-023-11880-2","journal-title":"J Neurol"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/JPR.S337216","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang X, Yue S, Liu J, Li S, Ma H et al (2022) Secular trends in the incidence of migraine in China from 1990 to 2019: a joinpoint and age-period-cohort analysis. J Pain Res 15:137\u2013146. https:\/\/doi.org\/10.2147\/JPR.S337216","journal-title":"J Pain Res"},{"issue":"1","key":"2382_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3988\/jcn.2021.17.1.77","volume":"17","author":"KM Kim","year":"2021","unstructured":"Kim KM, Cho SJ, Shin HJ, Yang KI, Kim D, Yun CH et al (2021) Prevalence, disability, and management patterns of migraine in Korea: nationwide survey data from 2009 and 2018. J Clin Neurol 17(1):77\u201385. https:\/\/doi.org\/10.3988\/jcn.2021.17.1.77","journal-title":"J Clin Neurol"},{"issue":"1","key":"2382_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S et al (2021) Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22(1):29. https:\/\/doi.org\/10.1186\/s10194-021-01243-5","journal-title":"J Headache Pain"},{"key":"2382_CR46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s10194-015-0533-5","volume":"16","author":"AC Yang","year":"2015","unstructured":"Yang AC, Fuh JL, Huang NE, Shia BC, Wang SJ (2015) Patients with migraine are right about their perception of temperature as a trigger: time series analysis of headache diary data. J Headache Pain 16:533. https:\/\/doi.org\/10.1186\/s10194-015-0533-5","journal-title":"J Headache Pain"},{"issue":"1","key":"2382_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/head.13670","volume":"60","author":"HH Lee","year":"2020","unstructured":"Lee HH, Chen CC, Ong JR, Lin YF, Lee FP, Hu CJ et al (2020) Association of rs2651899 polymorphism in the positive regulatory domain 16 and common migraine subtypes: a meta-analysis. Headache 60(1):71\u201380. https:\/\/doi.org\/10.1111\/head.13670","journal-title":"Headache"},{"key":"2382_CR48","doi-asserted-by":"publisher","unstructured":"Siokas V, Liampas I, Aloizou AM, Papasavva M, Bakirtzis C, Lavdas E et al (2022) Deciphering the role of the rs2651899, rs10166942, and rs11172113 polymorphisms in migraine: a meta-analysis. Med (Kaunas) 58(4). https:\/\/doi.org\/10.3390\/medicina58040491","DOI":"10.3390\/medicina58040491"},{"issue":"1","key":"2382_CR49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-019-1064-2","volume":"20","author":"YH Ling","year":"2019","unstructured":"Ling YH, Chen SP, Fann CS, Wang SJ, Wang YF (2019) TRPM8 genetic variant is associated with chronic migraine and allodynia. J Headache Pain 20(1):115. https:\/\/doi.org\/10.1186\/s10194-019-1064-2","journal-title":"J Headache Pain"},{"issue":"9","key":"2382_CR50","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/03331024221080891","volume":"42","author":"YF Wang","year":"2022","unstructured":"Wang YF, Liao YC, Tzeng YS, Chen SP, Lirng JF, Fuh JL et al (2022) Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura. Cephalalgia 42(9):888\u2013898. https:\/\/doi.org\/10.1177\/03331024221080891","journal-title":"Cephalalgia"},{"issue":"1","key":"2382_CR51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.12779\/dnd.2016.15.1.15","volume":"15","author":"JS Lee","year":"2016","unstructured":"Lee JS, Ko K, Oh JH, Park JH, Lee HK (2016) Phenotypic teatures of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy subjects with R544C mutation. Dement Neurocogn Disord 15(1):15\u201319. https:\/\/doi.org\/10.12779\/dnd.2016.15.1.15","journal-title":"Dement Neurocogn Disord"},{"key":"2382_CR52","doi-asserted-by":"publisher","first-page":"100227","DOI":"10.1016\/j.cccb.2024.100227","volume":"6","author":"G Boston","year":"2024","unstructured":"Boston G, Jobson D, Mizuno T, Ihara M, Kalaria RN (2024) Most common NOTCH3 mutations causing CADASIL or CADASIL-like cerebral small vessel disease: a systematic review. Cereb Circ Cogn Behav 6:100227. https:\/\/doi.org\/10.1016\/j.cccb.2024.100227","journal-title":"Cereb Circ Cogn Behav"},{"issue":"1","key":"2382_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10194-021-01301-y","volume":"22","author":"CK Tsai","year":"2021","unstructured":"Tsai CK, Liang CS, Lin GY, Tsai CL, Lee JT, Sung YF et al (2021) Identifying genetic variants for age of migraine onset in a Han Chinese population in Taiwan. J Headache Pain 22(1):89. https:\/\/doi.org\/10.1186\/s10194-021-01301-y","journal-title":"J Headache Pain"},{"issue":"9","key":"2382_CR54","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1007\/s00415-021-10720-5","volume":"268","author":"TH Massey","year":"2021","unstructured":"Massey TH, Robertson NP (2021) Medication-overuse headache: causes, consequences and management. J Neurol 268(9):3505\u20133507. https:\/\/doi.org\/10.1007\/s00415-021-10720-5","journal-title":"J Neurol"},{"issue":"1","key":"2382_CR55","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s10194-025-02172-3","volume":"26","author":"T Wijeratne","year":"2025","unstructured":"Wijeratne T, Martelletti P (2025) Ergotamine, triptans, and the global challenge of medication-overuse headache: a call to action from Asia-Oceania. J Headache Pain 26(1):228. https:\/\/doi.org\/10.1186\/s10194-025-02172-3","journal-title":"J Headache Pain"},{"issue":"6","key":"2382_CR56","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3760\/cma.j.cn113694-20230222-00118","volume":"56","author":"Y Wang","year":"2023","unstructured":"Chinese Society of Neurology, Headache Group of Chinese Society of Neurology, Wang Y, Wang Y (2023) Chinese practice guidelines for diagnosis and treatment of migraine. Chin J Neurol 56(6):591\u2013613. https:\/\/doi.org\/10.3760\/cma.j.cn113694-20230222-00118","journal-title":"Chin J Neurol"},{"issue":"10","key":"2382_CR57","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3969\/j.issn.1006-9852.2024.10.001","volume":"30","author":"Neurology Physicians Branch of the Chinese Medical Doctor Association","year":"2024","unstructured":"Neurology Physicians Branch of the Chinese Medical Doctor Association (2024) Chinese guidelines for the acute treatment of migraine. Chin J Pain Med 30(10):721\u2013734. https:\/\/doi.org\/10.3969\/j.issn.1006-9852.2024.10.001","journal-title":"Chin J Pain Med"},{"key":"2382_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ncn3.70042","volume":"13","author":"N Araki","year":"2025","unstructured":"Araki N, Takeshima T, Igarashi H, Shimizu T, Shibata M, Tatsumoto M et al (2025) Clinical practice guideline for headache disorders 2021. Neurol Clin Neurosci 13:389\u2013407. https:\/\/doi.org\/10.1111\/ncn3.70042","journal-title":"Neurol Clin Neurosci"},{"issue":"1","key":"2382_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2169\/internalmedicine.4846-24","volume":"65","author":"T Takeshima","year":"2026","unstructured":"Takeshima T, Kikui S, Danno D (2026) Migraine management in Japan: current approaches and science narrative including an evidence-based review. Intern Med 65(1):46\u201366. https:\/\/doi.org\/10.2169\/internalmedicine.4846-24","journal-title":"Intern Med"},{"key":"2382_CR60","unstructured":"Clinical practice huidelines for preventive treatment of migraine (2021). https:\/\/www.headache.or.kr\/m\/bbs\/board.php"},{"issue":"2","key":"2382_CR61","doi-asserted-by":"publisher","first-page":"100","DOI":"10.17340\/jkna.2020.2.3","volume":"38","author":"H-S Moon","year":"2020","unstructured":"Moon H-S, Park K-Y, Chung J-M, Kim B-K (2020) An update on migraine treatment. J Korean Neurol Assoc 38(2):100\u2013110. https:\/\/doi.org\/10.17340\/jkna.2020.2.3","journal-title":"J Korean Neurol Assoc"},{"issue":"2","key":"2382_CR62","first-page":"89","volume":"31","author":"CI Lau","year":"2022","unstructured":"Lau CI, Wang Y-F (2022) 2022 Taiwan guidelines for acute treatment of migraine. Acta Neurol Taiwan 31(2):89\u2013112","journal-title":"Acta Neurol Taiwan"},{"issue":"3","key":"2382_CR63","first-page":"164","volume":"31","author":"JW Wu","year":"2022","unstructured":"Wu JW, Yang CP (2022) 2022 Taiwan guidelines for preventive treatment of migraine. Acta Neurol Taiwan 31(3):164\u2013202","journal-title":"Acta Neurol Taiwan"},{"issue":"7","key":"2382_CR64","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61(7):1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"issue":"1","key":"2382_CR65","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","volume":"20","author":"S Sacco","year":"2019","unstructured":"Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6. https:\/\/doi.org\/10.1186\/s10194-018-0955-y","journal-title":"J Headache Pain"},{"key":"2382_CR66","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s10194-007-0366-y","volume":"1","author":"TJ Steiner","year":"2007","unstructured":"Steiner TJ, Paemeleire K, Jensen R, Valade D, Savi L, Lainez MJ et al (2007) European principles of management of common headache disorders in primary care. J Headache Pain Suppl 1:S3\u201347. https:\/\/doi.org\/10.1007\/s10194-007-0366-y","journal-title":"J Headache Pain Suppl"},{"issue":"1","key":"2382_CR67","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1129-2377-15-48","volume":"15","author":"TB Chen","year":"2014","unstructured":"Chen TB, Chen YT, Fuh JL, Tang CH, Wang SJ (2014) Treatment adherence among new triptan users: a 2-year cohort study in Taiwan. J Headache Pain 15(1):48. https:\/\/doi.org\/10.1186\/1129-2377-15-48","journal-title":"J Headache Pain"},{"key":"2382_CR68","doi-asserted-by":"publisher","first-page":"1222912","DOI":"10.3389\/fneur.2023.1222912","volume":"14","author":"YF Wang","year":"2023","unstructured":"Wang YF, Wang SJ, Huang YH, Chen YT, Yen YC, Shia BC et al (2023) Treatment pattern and health care resource utilization for Taiwanese patients with migraine: a population-based study. Front Neurol 14:1222912. https:\/\/doi.org\/10.3389\/fneur.2023.1222912","journal-title":"Front Neurol"},{"issue":"31","key":"2382_CR69","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3346\/jkms.2024.39.e222","volume":"39","author":"WS Ha","year":"2024","unstructured":"Ha WS, Jeong J, Song S, Yum J, Chu MK (2024) Trends in triptan usage in Korea: a population-based cohort study. J Korean Med Sci 39(31):e222. https:\/\/doi.org\/10.3346\/jkms.2024.39.e222","journal-title":"J Korean Med Sci"},{"issue":"1","key":"2382_CR70","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-020-01117-2","volume":"21","author":"S Yu","year":"2020","unstructured":"Yu S, Zhang Y, Yao Y, Cao H (2020) Migraine treatment and healthcare costs: retrospective analysis of The China Health Insurance Research Association (CHIRA) database. J Headache Pain 21(1):53. https:\/\/doi.org\/10.1186\/s10194-020-01117-2","journal-title":"J Headache Pain"},{"issue":"2","key":"2382_CR71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C (2014) Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 5(2):87\u201399. https:\/\/doi.org\/10.1177\/2042098614522683","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"2382_CR72","doi-asserted-by":"publisher","first-page":"16013","DOI":"10.1038\/s41598-024-66906-0","volume":"14","author":"SY Oh","year":"2024","unstructured":"Oh SY, Kang JJ, Park HK, Cho SJ, Hong Y, Kang MK et al (2024) Three-month treatment outcome of medication-overuse headache according to classes of overused medications, use of acute medications, and preventive treatments. Sci Rep 14(1):16013. https:\/\/doi.org\/10.1038\/s41598-024-66906-0","journal-title":"Sci Rep"},{"issue":"11","key":"2382_CR73","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/j.1468-2982.2008.01733.x","volume":"28","author":"SJ Wang","year":"2008","unstructured":"Wang SJ, Fuh JL (2008) Medication overuse headache in Taiwan. Cephalalgia 28(11):1240\u20131242. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01733.x","journal-title":"Cephalalgia"},{"key":"2382_CR74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/dhps.S304373","volume":"13","author":"F Lo Castro","year":"2021","unstructured":"Lo Castro F, Guerzoni S, Pellesi L (2021) Safety and risk of medication overuse headache in lasmiditan and second-generation gepants: a rapid review. Drug Healthc Patient Saf 13:233\u2013240. https:\/\/doi.org\/10.2147\/dhps.S304373","journal-title":"Drug Healthc Patient Saf"},{"key":"2382_CR75","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3760\/cma.j.cn113694-20230222-00120","volume":"56","author":"Y Wang","year":"2023","unstructured":"Chinese Society of Neurology, Headache Group of Chinese Society of Neurology, Wang Y, Wang Y (2023) Chinese practice guidelines for diagnosis and treatment of cluster headache. Chin J Neurol 56:626\u2013636. https:\/\/doi.org\/10.3760\/cma.j.cn113694-20230222-00120","journal-title":"Chin J Neurol"},{"issue":"1","key":"2382_CR76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.62087\/hpr.2024.0019","volume":"26","author":"B-S Kim","year":"2025","unstructured":"Kim B-S, Chung P-W, Chung JM, Park K-Y, Moon H-S, Park H-K et al (2025) Evidence-based recommendations on pharmacologic treatment for migraine prevention: a clinical practice guideline from The Korean Headache Society. Headache Pain Res 26(1):5\u201320","journal-title":"Headache Pain Res"},{"issue":"1","key":"2382_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-024-01737-y","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Ihara K, Watanabe N, Takemura R, Takahashi N, Miyazaki N et al (2024) CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache society. J Headache Pain 25(1):39. https:\/\/doi.org\/10.1186\/s10194-024-01737-y","journal-title":"J Headache Pain"},{"issue":"11","key":"2382_CR78","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM et al (2021) Comprehensive population-based survey of migraine in Japan: results of The ObserVational survey of The Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Curr Med Res Opin 37(11):1945\u20131955. https:\/\/doi.org\/10.1080\/03007995.2021.1971179","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2382_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s10194-024-01775-6","volume":"25","author":"J Huang","year":"2024","unstructured":"Huang J, Wang X, Jin Y, Lou G, Yu Z (2024) Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis. J Headache Pain 25(1):62. https:\/\/doi.org\/10.1186\/s10194-024-01775-6","journal-title":"J Headache Pain"},{"issue":"4","key":"2382_CR80","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3988\/jcn.2025.0021","volume":"21","author":"HJ Jeong","year":"2025","unstructured":"Jeong HJ, Lee MJ (2025) Real-world experience of lasmiditan for the acute treatment of migraine. J Clin Neurol 21(4):332\u2013339. https:\/\/doi.org\/10.3988\/jcn.2025.0021","journal-title":"J Clin Neurol"},{"issue":"7","key":"2382_CR81","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","volume":"42","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Mascarella D, Matteo E, Andrini G et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia 42(7):645\u2013653. https:\/\/doi.org\/10.1177\/03331024211067791","journal-title":"Cephalalgia"},{"issue":"5","key":"2382_CR82","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, Proietti S, D\u2019Onofrio F, Torelli P et al (2024) Ultra-late response (>\u200924 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol 271(5):2434\u20132443. https:\/\/doi.org\/10.1007\/s00415-023-12103-4","journal-title":"J Neurol"},{"issue":"1","key":"2382_CR83","doi-asserted-by":"publisher","first-page":"35","DOI":"10.24304\/kjcp.2021.31.1.35","volume":"31","author":"Y Kim","year":"2021","unstructured":"Kim Y, Park S, Kim E, Je NK (2021) Utilization of preventive therapy in Korean migraine patients. Korean J Clin Pharm 31(1):35\u201343. https:\/\/doi.org\/10.24304\/kjcp.2021.31.1.35","journal-title":"Korean J Clin Pharm"},{"issue":"1","key":"2382_CR84","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH et al (2022) Burden of migraine in Japan: results of The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Neurol Ther 11(1):205\u2013222. https:\/\/doi.org\/10.1007\/s40120-021-00305-9","journal-title":"Neurol Ther"},{"issue":"5","key":"2382_CR85","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/head.14721","volume":"64","author":"DC Buse","year":"2024","unstructured":"Buse DC, Sakai F, Matharu M, Reed ML, Fanning K, Dabruzzo B et al (2024) Characterizing gaps in the preventive pharmacologic treatment of migraine: multi-country results from The CaMEO-I study. Headache 64(5):469\u2013481. https:\/\/doi.org\/10.1111\/head.14721","journal-title":"Headache"},{"issue":"9","key":"2382_CR86","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1526-4610.2008.01088.x","volume":"48","author":"SJ Wang","year":"2008","unstructured":"Wang SJ, Chung CS, Chankrachang S, Ravishankar K, Merican JS, Salazar G et al (2008) Migraine disability awareness campaign in Asia: migraine assessment for prophylaxis. Headache 48(9):1356\u20131365. https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01088.x","journal-title":"Headache"},{"issue":"7","key":"2382_CR87","doi-asserted-by":"publisher","first-page":"e3547","DOI":"10.1002\/brb3.3547","volume":"14","author":"H Igarashi","year":"2024","unstructured":"Igarashi H, Komori M, Ueda K, Zagar AJ, Jaffe DH, Matsumori Y et al (2024) Underrecognition of migraine-related stigmatizing attitudes and social burden: results of The OVERCOME Japan study. Brain Behav 14(7):e3547. https:\/\/doi.org\/10.1002\/brb3.3547","journal-title":"Brain Behav"},{"key":"2382_CR88","doi-asserted-by":"publisher","unstructured":"Ljubisavljevic S, Ljubisavljevic M, Damjanovic R, Kalinic S (2023) A descriptive review of medication-overuse headache: from pathophysiology to the comorbidities. Brain Sci 13(10). https:\/\/doi.org\/10.3390\/brainsci13101408","DOI":"10.3390\/brainsci13101408"},{"issue":"1","key":"2382_CR89","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1129-2377-15-28","volume":"15","author":"MK Chu","year":"2014","unstructured":"Chu MK, Cho SJ, Kim JM, Hwang SH (2014) Field testing the alternative criteria for tension-type headache proposed in the third beta edition of the international classification of headache disorders: results from The Korean Headache-Sleep study. J Headache Pain 15(1):28. https:\/\/doi.org\/10.1186\/1129-2377-15-28","journal-title":"J Headache Pain"},{"issue":"2","key":"2382_CR90","doi-asserted-by":"publisher","first-page":"e14595","DOI":"10.1111\/cns.14595","volume":"30","author":"E Cresta","year":"2024","unstructured":"Cresta E, Bellotti A, Rinaldi G, Corbelli I, Sarchielli P (2024) Effect of anti-CGRP-targeted therapy on migraine aura: results of an observational case series study. CNS Neurosci Ther 30(2):e14595. https:\/\/doi.org\/10.1111\/cns.14595","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"2382_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"AH Society","year":"2019","unstructured":"Society AH (2019) The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59(1):1\u201318. https:\/\/doi.org\/10.1111\/head.13456","journal-title":"Headache"},{"issue":"1","key":"2382_CR92","first-page":"1","volume":"27","author":"MKIH Chu","year":"2009","unstructured":"Chu MKIH, Ju YS, Yu KH, Ma HI, Kim YJ, Kim J, Lee BC (2009) Validity and teliability assessment of Korean Headache Impact Test-6 (HIT-6). Korean Neurol Assoc 27(1):1\u20136","journal-title":"Korean Neurol Assoc"},{"issue":"1","key":"2382_CR93","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-021-01270-2","volume":"22","author":"BK Kim","year":"2021","unstructured":"Kim BK, Chu MK, Yu SJ, Dell\u2019Agnello G, Han JH, Cho SJ (2021) Burden of migraine and unmet needs from the patients\u2019 perspective: a survey across 11 specialized headache clinics in Korea. J Headache Pain 22(1):56. https:\/\/doi.org\/10.1186\/s10194-021-01270-2","journal-title":"J Headache Pain"},{"issue":"9","key":"2382_CR94","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/head.14606","volume":"63","author":"Y Matsumori","year":"2023","unstructured":"Matsumori Y, Ishida M, Iba K, Kim BK, Ning X, Nakai M et al (2023) Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: results of two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials. Headache 63(9):1304\u20131313. https:\/\/doi.org\/10.1111\/head.14606","journal-title":"Headache"},{"issue":"1","key":"2382_CR95","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s10194-022-01514-9","volume":"23","author":"S Yu","year":"2022","unstructured":"Yu S, Kim BK, Wang H, Zhou J, Wan Q, Yu T et al (2022) A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: The DRAGON study. J Headache Pain 23(1):146. https:\/\/doi.org\/10.1186\/s10194-022-01514-9","journal-title":"J Headache Pain"},{"issue":"7","key":"2382_CR96","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X et al (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102\u20131111. https:\/\/doi.org\/10.1111\/head.14178","journal-title":"Headache"},{"issue":"3","key":"2382_CR97","doi-asserted-by":"publisher","first-page":"251","DOI":"10.11607\/ofph.1769","volume":"31","author":"JG Seo","year":"2017","unstructured":"Seo JG, Park SP (2017) Validation of the Korean Migraine-Specific Quality of Life Questionnaire Version 2.1 in episodic and chronic migraine. J Oral Facial Pain Headache 31(3):251\u2013256. https:\/\/doi.org\/10.11607\/ofph.1769","journal-title":"J Oral Facial Pain Headache"},{"issue":"8","key":"2382_CR98","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/head.12878","volume":"56","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML (2016) A Comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache 56(8):1280\u20131289. https:\/\/doi.org\/10.1111\/head.12878","journal-title":"Headache"},{"issue":"1","key":"2382_CR99","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40120-023-00569-3","volume":"13","author":"E Awaki","year":"2024","unstructured":"Awaki E, Takeshima T, Matsumori Y, Hirata K, Miyazaki N, Takemura R et al (2024) Impact of migraine on daily life: results of The ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) study. Neurol Ther 13(1):165\u2013182. https:\/\/doi.org\/10.1007\/s40120-023-00569-3","journal-title":"Neurol Ther"},{"issue":"1","key":"2382_CR100","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, Ishii R, Hamakawa M, Tanizawa Y et al (2025) The impact of migraine on the whole life course of patients: results from The OVERCOME (Japan) 2nd study. Neurol Ther 14(1):335\u2013356. https:\/\/doi.org\/10.1007\/s40120-024-00690-x","journal-title":"Neurol Ther"},{"issue":"6","key":"2382_CR101","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22(6):476\u2013484. https:\/\/doi.org\/10.1016\/S1474-4422(23)00126-6","journal-title":"Lancet Neurol"},{"issue":"11","key":"2382_CR102","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/s1474-4422(18)30322-3","volume":"17","author":"GH Collaboration","year":"2018","unstructured":"Collaboration GH (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for The Global Burden of Disease study 2016. Lancet Neurol 17(11):954\u2013976. https:\/\/doi.org\/10.1016\/s1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"2382_CR103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11916-015-0531-y","volume":"20","author":"TH Lai","year":"2016","unstructured":"Lai TH, Wang SJ (2016) Update of inpatient treatment for refractory chronic daily headache. Curr Pain Headache Rep 20(1):5. https:\/\/doi.org\/10.1007\/s11916-015-0531-y","journal-title":"Curr Pain Headache Rep"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02382-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02382-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:07:32Z","timestamp":1782871652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02382-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02382-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}